The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 16, 2025

Filed:

Mar. 18, 2019
Applicant:

The Regents of the University of California, Oakland, CA (US);

Inventors:

John Matthew Timmerman, Los Angeles, CA (US);

Reiko King, Los Angeles, CA (US);

Patricia Young, Los Angeles, CA (US);

Alex Vasuthasawat, Los Angeles, CA (US);

Kham M. Trinh, Alhambra, CA (US);

Sherie Leaver Morrison, Los Angeles, CA (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/56 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 14/56 (2013.01); A61K 38/212 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2887 (2013.01); A61K 2239/48 (2023.05); C07K 2317/24 (2013.01); C07K 2317/526 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01);
Abstract

In various embodiments methods are provided that involve the use of antibody-interferon (Ab-IFN) fusion proteins to boost the cancer-fighting capacity of adoptive T cell therapies (ACT), including any T cells that are manipulated and grown outside the body, then returned to the patient with the goal of having the infused T cells home to sites of tumor and destroy the cancer in an immunologic attack. Illustrative, but non-limiting, adoptive T cell therapies include chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes (TILs), virus-specific T cells, and T cell receptor transgenic T cells.


Find Patent Forward Citations

Loading…